Dr. June Xu China

医疗基金
Company Size (Fulltime employees)
Year of foundation
2018
Partnering Objectives
Please specify your partnering goal
Investment opportunities
Headquartner in China
丹麓资本
Senior Associate 

Wenfeng Xu United States

Innovative biologics for cancer and other patients' unmet needs
Website:
Hengenix.com
Company Size (Fulltime employees)
Year of foundation
2010
Partnering Objectives
Please specify your partnering goal
co-dev
Headquartner in China
Hengenix
VP Research 

wenlian xu China

New drug development
Partnering Objectives
Headquartner in China
Biotech/Pharma Category
GH Therapeutics
CEO 

Mr. Kenneth Xu China

Genova Inc., a bio-pharma company dedicated in the innovation of better protein-drugs for viral diseases, cancer and auto-immune diseases. Novaferon ,the first novel protein drug of Genova, shows antiviral efficacy on viral clearance in a proof of concept randomized clinical trial and approved by Healthcare Canada and PMDA of Japan entering into phase 3 multinational centers clinical trial in last December. We are right looking for strategic parthership with big pharma. Contact: ctxu@genova.cn

Website:
www.genova.cn
Company Size (Fulltime employees)
Year of foundation
2006
Please specify your partnering goal
To work with a reputable pharmaceutical, or medical institute, or government agency, on scientific and business development of Novaferon as an antiviral drug for COVID-19. Cooperating specifically on organizing and managing international clinical trials, laboratory and animal studies for COVID-19. Licensing rights for COVID-19 applications of Novaferon in defined territories, further equity cooperation might be accordingly considered
Headquartner in China
Biotech/Pharma Category
Biotech/Pharma Asset Stage
Genova Inc
Vice President & Corporate Secretary 
Functionality

Mr. Paul Xu United States

The North American Representative Office of Shenzhen, P. R. China (NAROS) is a U.S. based, business service provider representing the City of Shenzhen, China´s first Special Economic Zone. Directly sponsored by the Shenzhen Municipal Government and Invest Shenzhen, NAROS offers guidance and consultation to North American companies wishing to enter the Chinese market by means of direct investment within in the City of Shenzhen, as well as to Shenzhen-based companies looking to enter the North American market.
Company Size (Fulltime employees)
Partnering Objectives
Please specify your partnering goal
providing consulting service for entities interested to find opportunities in Shenzhen
Headquartner in China
North American Rep. Office of Shenzhen
Business Development Specialist 
Functionality

John Xu United States

We have a very unique T-cell engager Bi-specific antibody platform.

Our COVID-19 neutralization antibody project is in phae 2 clinical tiral.

We have about 10 different Bi-specific projects in pre-clinical stage focusing on oncology, autoimmune and ophthomology.

We are looking for China partners to codevelop the Bi-specific antibodies.

We are also raising the capital to set up the CHina subsidiary.

You can add my wechat: elite8800

Website:
www.Abpro.com
Partnering Objectives
Headquartner in China
Abpro
SVP 

Mrs. Shirley Xu China

Yonghua Capital is an institutional investor, with headquarter in Shanghai and portfolio overseas. We have invested in over 40 companies in healthcare field over past 5 years.
Partnering Objectives
Headquartner in China
Yonghua Capital
Executive Director 
Functionality

Yuan Xudong United States

Please contact us using Acon Pharmaceutical Inc. 

Headquartner in China
Pharma - Acon Pharma
CEO 
Functionality